ISPOR Annual 2023

See the books

We'll be giving away 3 books contributed to by RTI Health Solutions experts. Come by the booth to register.

Schedule | Times listed are EDT

Short Courses, Sessions, and Forums

5/7/23 | 8:00AM - 12:00PM

Short Course

The Delphi Panel—from discord to actionable HEOR insights. Hundt Golden A, Gabriel MH, Price M.

5/8/23 | 3:15PM - 4:15PM

136: Forum

Towards broader relevance for HEOR: an HSPC visioning project. Willke R, McElwee N, Cole A, Berger M, Earnshaw S.

Stephanie Earnshaw speaking

5/8/23 | 4:45PM - 5:45PM

146: Session 3

External control arms (ECA) in phase 3 trials: what is needed now and in the future to enable acceptance with regulatory and HTA bodies? Karcher H, Hawe E, Gatto N, Jonsson P.

May 8, Poster Session 1, 9:45AM-1:15PM

CO11

Systematic literature review to evaluate randomized clinical trials of advanced therapies for moderate to severe crohn's disease. doi: 10.1016/j.jval.2023.03.085Yousif Z, Schultz BG, Candela N, Harold S, Bell J, Turpin R, Hartley L.

CO43

Burden of surgery in desmoid tumors. doi: 10.1016/j.jval.2023.03.117Fernandez M, Bell T, Tumminello B, Khan S, Zhou S, Oton AB.

EE41

Cost-utility of nivolumab versus observation for the adjuvant treatment of urothelial carcinoma (UC) for patients who are at high-risk of recurrence: a Canada public payer perspective. doi: 10.1016/j.jval.2023.03.347Graham J, Kassouf W, Tomaras D, Kurt M, Patel M, Teitsson S.

EE101

Use of patient-reported outcomes as key drivers in cost-effectiveness models: a review of UK National Institute for Health and Care Excellence health technology assessments. doi: 10.1016/j.jval.2023.03.405Dong O, Manga N, Zhong Y, Zhang Y, Krause T, Griffin J, Herring WL, Wolowacz S.

EPH45

Assessing the public health impact of the adjuvanted respiratory syncytial virus prefusion F protein vaccine among older adults in the United States (US). doi: 10.1016/j.jval.2023.03.927Molnar D, La E, Verelst F, Curran D, Poston S, Van Bellinghen LA, Graham J.

PCR20

Improvements in symptoms, impact of treatment, and satisfaction with treatment among patients with relapsed or refractory b-cell non-hodgkin lymphoma treated with subcutaneous epcoritamab. doi: 10.1016/j.jval.2023.03.1800Kosa K, Mutebi A, Wang A, Blaedel J, Sacchi M, Martin S.

Top 5% poster award recipient

May 8, Poster Session 2, 3:15-6:45PM

EPH90

Incidence rate of infections and association between lupus nephritis and serious infections in patients with systemic lupus erythematosus: systematic literature review and meta-analyses. doi: 10.1016/j.jval.2023.03.972Nangia A, Simou E, Abeysinghe S, Colosia A, Bektas M, Workman J, Gao S, Bello N.

PCR74

Trends in the inclusion of patient reported outcomes in oncology clinical trials: analysis of clinicaltrials.gov (2013-2022). doi: 10.1016/j.jval.2023.03.1852Mordin M, Castro C, Gnanasakthy A.

PCR98

A literature review assessing the most common attributes used in stated-preference studies assessing influenza vaccination: do we know what health care professionals value? doi: 10.1016/j.jval.2023.03.1876McMichael A, Poulos C, Vass C, Boeri M.

May 9, Poster Session 3, 9:45AM-1:15PM

EE310

Relationships among sickle cell disease complications and their implications for cost-effectiveness modeling for therapies with curative intent. doi: 10.1016/j.jval.2023.03.611Dong O, Purser M, Herring WL, Mladsi DM, Gallagher M, Chawla A, Leiding JW, Andemariam B.

EE331

Leveraging time-use data to estimate market and non-market productivity losses due to respiratory syncytial virus (RSV) disease among adults aged ≥60 years in the United States (US). doi: 10.1016/j.jval.2023.03.632Verelst F, La E, Graham J, Molnar D.

EPH131

Estimation of the population of patients eligible for pirtobrutinib after Covalent Bruton Tyrosine Kinase Inhibitor (CBTKI) discontinuation in the United States. doi: 10.1016/j.jval.2023.03.1013Zhang KH, Winfree K, Taipale KL, Muehlenbein CE, Panjic EH, Graham C.

RWD92

Prevalence and factors associated with the use of direct oral anticoagulants and low molecular weight heparins (LMWH) in cancer patients. doi: 10.1016/j.jval.2023.03.2121Johnson ML, Yande S, Aparasu RR, Wanat M, Toale K.

May 9, Poster Session 4, 3:15-6:45PM

CO162

A retrospective medical record review of first-line sunitinib administration schedules and outcomes among patients with metastatic renal cell carcinoma in Latin America. doi: 10.1016/j.jval.2023.03.2298Jimenez M, Zanotti G, Parikh RC, Esterberg E, Suarez LA.

EE356

Health care resource use and medical costs attributable to respiratory syncytial virus (RSV) among adults ≥60 years of age in the United States: a retrospective claims database analysis. doi: 10.1016/j.jval.2023.03.657Aris E, Brabant Y, La E, Candrilli S, Molnar D.

EPH183

Impact of a cancer diagnosis on non-cancer chronic disease medication adherence - a systematic literature review. doi: 10.1016/j.jval.2023.03.1064Gohil S, Johnson ML, Goyal R.

HTA74

HTA processes for medical technologies across the world – are all hurdles the same? doi: 10.1016/j.jval.2023.03.1503Mordin M, Gildea LJ, Warttig S, Costello J, D'Souza V, Kinderås M, Ling C, Marcano Belisario J.

PCR167

Patient preferences for lung cancer interception therapy. doi: 10.1016/j.jval.2023.03.1943Janssen E, Smith I, Liu X, Mansfield C, Pierce A, Huang Q, Kalsekar I.

PCR191

A review of the influence of stakeholder preference research on the EtR framework. doi: 10.1016/j.jval.2023.03.2370Poulos C, Pierce A, Chintakayala PK.

PCR249

Advancing equity, diversity, inclusion, and belonging in patient centered drug development with patient preference research. doi: 10.1016/j.jval.2023.03.2791Poulos C, Mansfield C, Bussberg CJ, Hicks JC, Downey C.

May 10, Poster Session 5, 8:30-11:30AM

EE522

Healthcare resource use and costs among patients with erythropoietic protoporphyria and x-linked protoporphyria in the United States. doi: 10.1016/j.jval.2023.03.2501Houghton K, Hitchens A, Ciepielewska M.

PCR199

Benefit-risk preferences of patients for the use of artificial intelligence and ultrasound imaging in different settings in echocardiography. doi: 10.1016/j.jval.2023.03.2378Poulos C, Gebben D, Peay H, Saha A, Vaezy S, Pierce A, Pina I, Farb A, Moultrie R, Babalola O, Tarver ME.

PCR216

Insights from social media posts on the lived experience of alzheimer's disease. doi: 10.1016/j.jval.2023.03.2395Frederiksen KS, Crawford R, Hahn-Pedersen JH, Morrison R, Jeppesen R, Doward L, Weidner W.

Research and course previews

Equity, diversity, inclusion, and belonging in patient centered drug development

Chad Downey, BS, Associate Director, Project and Proposal Operations at RTI Health Solutions, discusses research being presented at ISPOR on advancing equity, diversity, inclusion, and belonging in patient centered drug development with patient preference research.

Trends in the inclusion of patient reported outcomes in oncology clinical trials

Margaret Mordin, MS, Vice President, Market Access and Outcomes Strategy at RTI Health Solutions, discusses research on Trends in the inclusion of patient reported outcomes in oncology clinical trials: analysis of clinicaltrials.gov (2013-2022).

The Delphi Panel—from discord to actionable HEOR insights

Mark Price, MEd, MA, Head, Economic QUalitative Inquiry, Policy, and Access at RTI Health Solutions discusses a new workshop he and his colleagues will be presenting at ISPOR.

Meet our experts who will be in Boston at ISPOR

Susan Barker, BA

Senior Director, Marketing-Digital Strategy

ISPOR Annual 2023

Impacting Innovation, Value, and Healthcare Decision Making

Schedule | Times listed are EDT

Research and course previews

Meet our experts who will be in Boston at ISPOR

Enter our Book Giveaway!